Evaluation of the Clinical use of Metformin or Pioglitazone in Combination with Meloxicam in Patients with Knee Osteoarthritis; using Knee Injury and Osteoarthritis outcome Score Article Swipe
Mohammed M. Mohammed
,
Kassim J. Al-Shamma
,
Nizar Abdulateef Jassim
·
YOU?
·
· 2017
· Open Access
·
· DOI: https://doi.org/10.31351/vol23iss2pp13-23
YOU?
·
· 2017
· Open Access
·
· DOI: https://doi.org/10.31351/vol23iss2pp13-23
Osteoarthritis is the most prevalent arthritic disease and a leading cause of disability. The pathogenesis of osteoarthritis involves multiple etiologies, including variable degree of synovial inflammation. Metformin and pioglitazone could potentially reduce the levels and activity of inflammatory mediators. This may consider as a new therapeutic approach added to the current used drugs in an attempt to decrease the pain, inflammation, and improve daily activity and quality of life in patients with knee osteoarthritis. This study designed to evaluate the clinical utility of using metformin or pioglitazone as anti-inflammatory agents in combination with non-steroidal anti-inflammatory drugs (NSAID) of selective type of cyclooxygenase-2 (COX-2) inhibitor, meloxicam, in the treatment of knee osteoarthritis (OA). Randomized, double blinded clinical study was performed on 98 patients who have symptomatic and radiologic evidence of painful OA of the knee (57 patients only completed the study). Patients were allocated into three groups, group (A); 20 patients treated with meloxicam (15mg/day) alone, group (B); 20 patients treated with metformin (1000mg/day) + meloxicam (15mg/day) and group (C); 17 patients treated with pioglitazone (15mg/day) + meloxicam (15mg/day). The treatment was followed for 12 weeks through measurement of the clinical effects of drugs each 7 days, using the Knee Injury and Osteoarthritis Outcome Score (KOOS) system. The results showed that metformin or pioglitazone, when used in combination with NSAID resulted in significant improvement in the components of KOOS, higher than that produced by meloxicam when used alone. In conclusion, administration of metformin or pioglitazone as adjuvant therapy to NSAID, meloxicam, in OA patients produced very well characterized analgesic and anti-inflammatory activities, and improves the therapeutic profile of meloxicam. Keywords: Metformin, Pioglitazone, Osteoarthritis, Knee injury, KOOS.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.31351/vol23iss2pp13-23
- https://bijps.uobaghdad.edu.iq/index.php/bijps/article/download/384/317
- OA Status
- diamond
- Cited By
- 24
- References
- 36
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W2612931059
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W2612931059Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.31351/vol23iss2pp13-23Digital Object Identifier
- Title
-
Evaluation of the Clinical use of Metformin or Pioglitazone in Combination with Meloxicam in Patients with Knee Osteoarthritis; using Knee Injury and Osteoarthritis outcome ScoreWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2017Year of publication
- Publication date
-
2017-03-27Full publication date if available
- Authors
-
Mohammed M. Mohammed, Kassim J. Al-Shamma, Nizar Abdulateef JassimList of authors in order
- Landing page
-
https://doi.org/10.31351/vol23iss2pp13-23Publisher landing page
- PDF URL
-
https://bijps.uobaghdad.edu.iq/index.php/bijps/article/download/384/317Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
diamondOpen access status per OpenAlex
- OA URL
-
https://bijps.uobaghdad.edu.iq/index.php/bijps/article/download/384/317Direct OA link when available
- Concepts
-
Meloxicam, Medicine, Pioglitazone, Osteoarthritis, Metformin, Internal medicine, Diabetes mellitus, Type 2 diabetes, Endocrinology, Pathology, Insulin, Alternative medicineTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
24Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 5, 2024: 4, 2023: 5, 2022: 5, 2021: 1Per-year citation counts (last 5 years)
- References (count)
-
36Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W2612931059 |
|---|---|
| doi | https://doi.org/10.31351/vol23iss2pp13-23 |
| ids.doi | https://doi.org/10.31351/vol23iss2pp13-23 |
| ids.mag | 2612931059 |
| ids.openalex | https://openalex.org/W2612931059 |
| fwci | 0.64842933 |
| type | article |
| title | Evaluation of the Clinical use of Metformin or Pioglitazone in Combination with Meloxicam in Patients with Knee Osteoarthritis; using Knee Injury and Osteoarthritis outcome Score |
| biblio.issue | 2 |
| biblio.volume | 23 |
| biblio.last_page | 23 |
| biblio.first_page | 13 |
| topics[0].id | https://openalex.org/T10678 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9994000196456909 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2736 |
| topics[0].subfield.display_name | Pharmacology |
| topics[0].display_name | Inflammatory mediators and NSAID effects |
| topics[1].id | https://openalex.org/T10274 |
| topics[1].field.id | https://openalex.org/fields/16 |
| topics[1].field.display_name | Chemistry |
| topics[1].score | 0.996999979019165 |
| topics[1].domain.id | https://openalex.org/domains/3 |
| topics[1].domain.display_name | Physical Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1605 |
| topics[1].subfield.display_name | Organic Chemistry |
| topics[1].display_name | Synthesis and biological activity |
| topics[2].id | https://openalex.org/T10817 |
| topics[2].field.id | https://openalex.org/fields/16 |
| topics[2].field.display_name | Chemistry |
| topics[2].score | 0.9923999905586243 |
| topics[2].domain.id | https://openalex.org/domains/3 |
| topics[2].domain.display_name | Physical Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1605 |
| topics[2].subfield.display_name | Organic Chemistry |
| topics[2].display_name | Multicomponent Synthesis of Heterocycles |
| is_xpac | False |
| apc_list.value | 250000 |
| apc_list.currency | IQD |
| apc_list.value_usd | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2779751750 |
| concepts[0].level | 2 |
| concepts[0].score | 0.9624318480491638 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q414028 |
| concepts[0].display_name | Meloxicam |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.9273303747177124 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C2778384471 |
| concepts[2].level | 4 |
| concepts[2].score | 0.906451940536499 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q417765 |
| concepts[2].display_name | Pioglitazone |
| concepts[3].id | https://openalex.org/C2776164576 |
| concepts[3].level | 3 |
| concepts[3].score | 0.8908599615097046 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q62736 |
| concepts[3].display_name | Osteoarthritis |
| concepts[4].id | https://openalex.org/C2780323712 |
| concepts[4].level | 3 |
| concepts[4].score | 0.6838091015815735 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q19484 |
| concepts[4].display_name | Metformin |
| concepts[5].id | https://openalex.org/C126322002 |
| concepts[5].level | 1 |
| concepts[5].score | 0.4820738434791565 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[5].display_name | Internal medicine |
| concepts[6].id | https://openalex.org/C555293320 |
| concepts[6].level | 2 |
| concepts[6].score | 0.14936697483062744 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q12206 |
| concepts[6].display_name | Diabetes mellitus |
| concepts[7].id | https://openalex.org/C2777180221 |
| concepts[7].level | 3 |
| concepts[7].score | 0.12359559535980225 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q3025883 |
| concepts[7].display_name | Type 2 diabetes |
| concepts[8].id | https://openalex.org/C134018914 |
| concepts[8].level | 1 |
| concepts[8].score | 0.10467958450317383 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q162606 |
| concepts[8].display_name | Endocrinology |
| concepts[9].id | https://openalex.org/C142724271 |
| concepts[9].level | 1 |
| concepts[9].score | 0.08642405271530151 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q7208 |
| concepts[9].display_name | Pathology |
| concepts[10].id | https://openalex.org/C2779306644 |
| concepts[10].level | 2 |
| concepts[10].score | 0.0 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q2002370 |
| concepts[10].display_name | Insulin |
| concepts[11].id | https://openalex.org/C204787440 |
| concepts[11].level | 2 |
| concepts[11].score | 0.0 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q188504 |
| concepts[11].display_name | Alternative medicine |
| keywords[0].id | https://openalex.org/keywords/meloxicam |
| keywords[0].score | 0.9624318480491638 |
| keywords[0].display_name | Meloxicam |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.9273303747177124 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/pioglitazone |
| keywords[2].score | 0.906451940536499 |
| keywords[2].display_name | Pioglitazone |
| keywords[3].id | https://openalex.org/keywords/osteoarthritis |
| keywords[3].score | 0.8908599615097046 |
| keywords[3].display_name | Osteoarthritis |
| keywords[4].id | https://openalex.org/keywords/metformin |
| keywords[4].score | 0.6838091015815735 |
| keywords[4].display_name | Metformin |
| keywords[5].id | https://openalex.org/keywords/internal-medicine |
| keywords[5].score | 0.4820738434791565 |
| keywords[5].display_name | Internal medicine |
| keywords[6].id | https://openalex.org/keywords/diabetes-mellitus |
| keywords[6].score | 0.14936697483062744 |
| keywords[6].display_name | Diabetes mellitus |
| keywords[7].id | https://openalex.org/keywords/type-2-diabetes |
| keywords[7].score | 0.12359559535980225 |
| keywords[7].display_name | Type 2 diabetes |
| keywords[8].id | https://openalex.org/keywords/endocrinology |
| keywords[8].score | 0.10467958450317383 |
| keywords[8].display_name | Endocrinology |
| keywords[9].id | https://openalex.org/keywords/pathology |
| keywords[9].score | 0.08642405271530151 |
| keywords[9].display_name | Pathology |
| language | en |
| locations[0].id | doi:10.31351/vol23iss2pp13-23 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2764399167 |
| locations[0].source.issn | 1683-3597, 2521-3512 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1683-3597 |
| locations[0].source.is_core | False |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512) |
| locations[0].source.host_organization | |
| locations[0].source.host_organization_name | |
| locations[0].source.host_organization_lineage | |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://bijps.uobaghdad.edu.iq/index.php/bijps/article/download/384/317 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512) |
| locations[0].landing_page_url | https://doi.org/10.31351/vol23iss2pp13-23 |
| locations[1].id | pmh:oai:doaj.org/article:ab813a1c030b4799b37a4f3c228aeaf6 |
| locations[1].is_oa | True |
| locations[1].source.id | https://openalex.org/S4306401280 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[1].source.host_organization | |
| locations[1].source.host_organization_name | |
| locations[1].source.host_organization_lineage | |
| locations[1].license | cc-by-sa |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | article |
| locations[1].license_id | https://openalex.org/licenses/cc-by-sa |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | Iraqi Journal of Pharmaceutical Sciences, Vol 23, Iss 2 (2017) |
| locations[1].landing_page_url | https://doaj.org/article/ab813a1c030b4799b37a4f3c228aeaf6 |
| indexed_in | crossref, doaj |
| authorships[0].author.id | https://openalex.org/A5111138606 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Mohammed M. Mohammed |
| authorships[0].countries | IQ |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I15873915 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Clinical Pharmacy, College of Pharmacy, University of Al-Mustansiryah, Baghdad, Iraq. |
| authorships[0].affiliations[1].institution_ids | https://openalex.org/I135120706 |
| authorships[0].affiliations[1].raw_affiliation_string | Department of Therapeutics and Clinical Pharmaceutics, Baghdad College of Pharmacy, Baghdad, Iraq. |
| authorships[0].institutions[0].id | https://openalex.org/I15873915 |
| authorships[0].institutions[0].ror | https://ror.org/05s04wy35 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I15873915 |
| authorships[0].institutions[0].country_code | IQ |
| authorships[0].institutions[0].display_name | Mustansiriyah University |
| authorships[0].institutions[1].id | https://openalex.org/I135120706 |
| authorships[0].institutions[1].ror | https://ror.org/007f1da21 |
| authorships[0].institutions[1].type | education |
| authorships[0].institutions[1].lineage | https://openalex.org/I135120706 |
| authorships[0].institutions[1].country_code | IQ |
| authorships[0].institutions[1].display_name | University of Baghdad |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Mohammed M. Mohammed |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Clinical Pharmacy, College of Pharmacy, University of Al-Mustansiryah, Baghdad, Iraq., Department of Therapeutics and Clinical Pharmaceutics, Baghdad College of Pharmacy, Baghdad, Iraq. |
| authorships[1].author.id | https://openalex.org/A5021838582 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Kassim J. Al-Shamma |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Kassim J. Al-Shamma |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5028962066 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-0659-8130 |
| authorships[2].author.display_name | Nizar Abdulateef Jassim |
| authorships[2].author_position | last |
| authorships[2].raw_author_name | Nizar A. Jassim |
| authorships[2].is_corresponding | False |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://bijps.uobaghdad.edu.iq/index.php/bijps/article/download/384/317 |
| open_access.oa_status | diamond |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Evaluation of the Clinical use of Metformin or Pioglitazone in Combination with Meloxicam in Patients with Knee Osteoarthritis; using Knee Injury and Osteoarthritis outcome Score |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10678 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9994000196456909 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2736 |
| primary_topic.subfield.display_name | Pharmacology |
| primary_topic.display_name | Inflammatory mediators and NSAID effects |
| related_works | https://openalex.org/W3142910047, https://openalex.org/W2471768190, https://openalex.org/W2965513749, https://openalex.org/W1967713685, https://openalex.org/W2057743727, https://openalex.org/W46097970, https://openalex.org/W2402705660, https://openalex.org/W2254484345, https://openalex.org/W3187729126, https://openalex.org/W3031436363 |
| cited_by_count | 24 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 5 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 4 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 5 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 5 |
| counts_by_year[4].year | 2021 |
| counts_by_year[4].cited_by_count | 1 |
| counts_by_year[5].year | 2019 |
| counts_by_year[5].cited_by_count | 2 |
| counts_by_year[6].year | 2018 |
| counts_by_year[6].cited_by_count | 1 |
| counts_by_year[7].year | 2016 |
| counts_by_year[7].cited_by_count | 1 |
| locations_count | 2 |
| best_oa_location.id | doi:10.31351/vol23iss2pp13-23 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2764399167 |
| best_oa_location.source.issn | 1683-3597, 2521-3512 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1683-3597 |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512) |
| best_oa_location.source.host_organization | |
| best_oa_location.source.host_organization_name | |
| best_oa_location.source.host_organization_lineage | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://bijps.uobaghdad.edu.iq/index.php/bijps/article/download/384/317 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512) |
| best_oa_location.landing_page_url | https://doi.org/10.31351/vol23iss2pp13-23 |
| primary_location.id | doi:10.31351/vol23iss2pp13-23 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2764399167 |
| primary_location.source.issn | 1683-3597, 2521-3512 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1683-3597 |
| primary_location.source.is_core | False |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512) |
| primary_location.source.host_organization | |
| primary_location.source.host_organization_name | |
| primary_location.source.host_organization_lineage | |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://bijps.uobaghdad.edu.iq/index.php/bijps/article/download/384/317 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512) |
| primary_location.landing_page_url | https://doi.org/10.31351/vol23iss2pp13-23 |
| publication_date | 2017-03-27 |
| publication_year | 2017 |
| referenced_works | https://openalex.org/W40893476, https://openalex.org/W6781929166, https://openalex.org/W2275249742, https://openalex.org/W2061134044, https://openalex.org/W1979624317, https://openalex.org/W2052893433, https://openalex.org/W2150288864, https://openalex.org/W2017505271, https://openalex.org/W2149287982, https://openalex.org/W2020960323, https://openalex.org/W4285719527, https://openalex.org/W2121386098, https://openalex.org/W2035630396, https://openalex.org/W2150849143, https://openalex.org/W2056146193, https://openalex.org/W2107894170, https://openalex.org/W1992724479, https://openalex.org/W2331672431, https://openalex.org/W2167248983, https://openalex.org/W2266185506, https://openalex.org/W93243307, https://openalex.org/W2087598895, https://openalex.org/W2008062764, https://openalex.org/W2332679000, https://openalex.org/W2168172569, https://openalex.org/W83491348, https://openalex.org/W1568585026, https://openalex.org/W2117889502, https://openalex.org/W1986064724, https://openalex.org/W2328721585, https://openalex.org/W2108587119, https://openalex.org/W2062389193, https://openalex.org/W2054408377, https://openalex.org/W1985719155, https://openalex.org/W2118200369, https://openalex.org/W2261890046 |
| referenced_works_count | 36 |
| abstract_inverted_index.+ | 163, 175 |
| abstract_inverted_index.7 | 194 |
| abstract_inverted_index.a | 8, 43 |
| abstract_inverted_index.12 | 183 |
| abstract_inverted_index.17 | 169 |
| abstract_inverted_index.20 | 148, 157 |
| abstract_inverted_index.98 | 120 |
| abstract_inverted_index.In | 237 |
| abstract_inverted_index.OA | 130, 251 |
| abstract_inverted_index.an | 54 |
| abstract_inverted_index.as | 42, 87, 244 |
| abstract_inverted_index.by | 232 |
| abstract_inverted_index.in | 53, 69, 90, 105, 215, 220, 223, 250 |
| abstract_inverted_index.is | 1 |
| abstract_inverted_index.of | 11, 15, 23, 36, 67, 82, 97, 100, 108, 128, 131, 187, 191, 226, 240, 266 |
| abstract_inverted_index.on | 119 |
| abstract_inverted_index.or | 85, 211, 242 |
| abstract_inverted_index.to | 48, 56, 77, 247 |
| abstract_inverted_index.(57 | 134 |
| abstract_inverted_index.The | 13, 178, 206 |
| abstract_inverted_index.and | 7, 27, 34, 61, 65, 125, 166, 200, 258, 261 |
| abstract_inverted_index.for | 182 |
| abstract_inverted_index.may | 40 |
| abstract_inverted_index.new | 44 |
| abstract_inverted_index.the | 2, 32, 49, 58, 79, 106, 132, 138, 188, 197, 224, 263 |
| abstract_inverted_index.was | 117, 180 |
| abstract_inverted_index.who | 122 |
| abstract_inverted_index.(A); | 147 |
| abstract_inverted_index.(B); | 156 |
| abstract_inverted_index.(C); | 168 |
| abstract_inverted_index.Knee | 198, 272 |
| abstract_inverted_index.This | 39, 74 |
| abstract_inverted_index.each | 193 |
| abstract_inverted_index.have | 123 |
| abstract_inverted_index.into | 143 |
| abstract_inverted_index.knee | 72, 109, 133 |
| abstract_inverted_index.life | 68 |
| abstract_inverted_index.most | 3 |
| abstract_inverted_index.only | 136 |
| abstract_inverted_index.than | 229 |
| abstract_inverted_index.that | 209, 230 |
| abstract_inverted_index.type | 99 |
| abstract_inverted_index.used | 51, 214, 235 |
| abstract_inverted_index.very | 254 |
| abstract_inverted_index.well | 255 |
| abstract_inverted_index.were | 141 |
| abstract_inverted_index.when | 213, 234 |
| abstract_inverted_index.with | 71, 92, 151, 160, 172, 217 |
| abstract_inverted_index.KOOS, | 227 |
| abstract_inverted_index.KOOS. | 274 |
| abstract_inverted_index.NSAID | 218 |
| abstract_inverted_index.Score | 203 |
| abstract_inverted_index.added | 47 |
| abstract_inverted_index.cause | 10 |
| abstract_inverted_index.could | 29 |
| abstract_inverted_index.daily | 63 |
| abstract_inverted_index.days, | 195 |
| abstract_inverted_index.drugs | 52, 95, 192 |
| abstract_inverted_index.group | 146, 155, 167 |
| abstract_inverted_index.pain, | 59 |
| abstract_inverted_index.study | 75, 116 |
| abstract_inverted_index.three | 144 |
| abstract_inverted_index.using | 83, 196 |
| abstract_inverted_index.weeks | 184 |
| abstract_inverted_index.(KOOS) | 204 |
| abstract_inverted_index.Injury | 199 |
| abstract_inverted_index.NSAID, | 248 |
| abstract_inverted_index.agents | 89 |
| abstract_inverted_index.alone, | 154 |
| abstract_inverted_index.alone. | 236 |
| abstract_inverted_index.degree | 22 |
| abstract_inverted_index.double | 113 |
| abstract_inverted_index.higher | 228 |
| abstract_inverted_index.levels | 33 |
| abstract_inverted_index.reduce | 31 |
| abstract_inverted_index.showed | 208 |
| abstract_inverted_index.(COX-2) | 102 |
| abstract_inverted_index.(NSAID) | 96 |
| abstract_inverted_index.Outcome | 202 |
| abstract_inverted_index.attempt | 55 |
| abstract_inverted_index.blinded | 114 |
| abstract_inverted_index.current | 50 |
| abstract_inverted_index.disease | 6 |
| abstract_inverted_index.effects | 190 |
| abstract_inverted_index.groups, | 145 |
| abstract_inverted_index.improve | 62 |
| abstract_inverted_index.injury, | 273 |
| abstract_inverted_index.leading | 9 |
| abstract_inverted_index.painful | 129 |
| abstract_inverted_index.profile | 265 |
| abstract_inverted_index.quality | 66 |
| abstract_inverted_index.results | 207 |
| abstract_inverted_index.study). | 139 |
| abstract_inverted_index.therapy | 246 |
| abstract_inverted_index.through | 185 |
| abstract_inverted_index.treated | 150, 159, 171 |
| abstract_inverted_index.utility | 81 |
| abstract_inverted_index.Patients | 140 |
| abstract_inverted_index.activity | 35, 64 |
| abstract_inverted_index.adjuvant | 245 |
| abstract_inverted_index.approach | 46 |
| abstract_inverted_index.clinical | 80, 115, 189 |
| abstract_inverted_index.consider | 41 |
| abstract_inverted_index.decrease | 57 |
| abstract_inverted_index.designed | 76 |
| abstract_inverted_index.evaluate | 78 |
| abstract_inverted_index.evidence | 127 |
| abstract_inverted_index.followed | 181 |
| abstract_inverted_index.improves | 262 |
| abstract_inverted_index.involves | 17 |
| abstract_inverted_index.multiple | 18 |
| abstract_inverted_index.patients | 70, 121, 135, 149, 158, 170, 252 |
| abstract_inverted_index.produced | 231, 253 |
| abstract_inverted_index.resulted | 219 |
| abstract_inverted_index.synovial | 24 |
| abstract_inverted_index.variable | 21 |
| abstract_inverted_index.Keywords: | 268 |
| abstract_inverted_index.Metformin | 26 |
| abstract_inverted_index.allocated | 142 |
| abstract_inverted_index.analgesic | 257 |
| abstract_inverted_index.arthritic | 5 |
| abstract_inverted_index.completed | 137 |
| abstract_inverted_index.including | 20 |
| abstract_inverted_index.meloxicam | 152, 164, 176, 233 |
| abstract_inverted_index.metformin | 84, 161, 210, 241 |
| abstract_inverted_index.performed | 118 |
| abstract_inverted_index.prevalent | 4 |
| abstract_inverted_index.selective | 98 |
| abstract_inverted_index.treatment | 107, 179 |
| abstract_inverted_index.(15mg/day) | 153, 165, 174 |
| abstract_inverted_index.Metformin, | 269 |
| abstract_inverted_index.components | 225 |
| abstract_inverted_index.inhibitor, | 103 |
| abstract_inverted_index.mediators. | 38 |
| abstract_inverted_index.meloxicam, | 104, 249 |
| abstract_inverted_index.radiologic | 126 |
| abstract_inverted_index.(15mg/day). | 177 |
| abstract_inverted_index.(OA).
 | 111 |
| abstract_inverted_index.Randomized, | 112 |
| abstract_inverted_index.activities, | 260 |
| abstract_inverted_index.combination | 91, 216 |
| abstract_inverted_index.conclusion, | 238 |
| abstract_inverted_index.disability. | 12 |
| abstract_inverted_index.etiologies, | 19 |
| abstract_inverted_index.improvement | 222 |
| abstract_inverted_index.measurement | 186 |
| abstract_inverted_index.potentially | 30 |
| abstract_inverted_index.significant | 221 |
| abstract_inverted_index.symptomatic | 124 |
| abstract_inverted_index.therapeutic | 45, 264 |
| abstract_inverted_index.(1000mg/day) | 162 |
| abstract_inverted_index.inflammatory | 37 |
| abstract_inverted_index.pathogenesis | 14 |
| abstract_inverted_index.pioglitazone | 28, 86, 173, 243 |
| abstract_inverted_index.Pioglitazone, | 270 |
| abstract_inverted_index.characterized | 256 |
| abstract_inverted_index.inflammation, | 60 |
| abstract_inverted_index.inflammation. | 25 |
| abstract_inverted_index.non-steroidal | 93 |
| abstract_inverted_index.pioglitazone, | 212 |
| abstract_inverted_index.system.
 | 205 |
| abstract_inverted_index.Osteoarthritis | 0, 201 |
| abstract_inverted_index.administration | 239 |
| abstract_inverted_index.osteoarthritis | 16, 110 |
| abstract_inverted_index.Osteoarthritis, | 271 |
| abstract_inverted_index.cyclooxygenase-2 | 101 |
| abstract_inverted_index.meloxicam.
 | 267 |
| abstract_inverted_index.anti-inflammatory | 88, 94, 259 |
| abstract_inverted_index.osteoarthritis.
 | 73 |
| cited_by_percentile_year.max | 99 |
| cited_by_percentile_year.min | 89 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 3 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.6800000071525574 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.67701673 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |